{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-24-000149","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.491460+00:00","generated_at":"2026-05-30T08:51:21.246471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance","bullets":["Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.","GAAP diluted EPS $0.55 (+162%); Non-GAAP diluted EPS $0.91 (+98%).","Raised full-year 2024 guidance for total revenue, Non-GAAP operating margin, and Non-GAAP EPS.","Retired $495M convertible debt in cash, eliminating ~4M dilutive shares.","Over 3,800 children on VOXZOGO; majority of US new starts under age 5."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-24-000149","json":"https://secwatch.observer/filing/0001048477-24-000149.json","markdown":"https://secwatch.observer/filing/0001048477-24-000149.md","text":"https://secwatch.observer/filing/0001048477-24-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/0001048477-24-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/bmrn-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:51:21.246471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}